Bank of America Boosts Aardvark Therapeutics (NASDAQ:AARD) Price Target to $26.00

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) had its target price boosted by research analysts at Bank of America from $22.00 to $26.00 in a research note issued on Thursday, MarketBeat Ratings reports. The brokerage currently has a "buy" rating on the stock. Bank of America's price target would indicate a potential upside of 259.12% from the stock's current price.

AARD has been the topic of several other research reports. Cantor Fitzgerald assumed coverage on shares of Aardvark Therapeutics in a report on Monday, March 10th. They set an "overweight" rating and a $50.00 target price on the stock. Morgan Stanley started coverage on Aardvark Therapeutics in a research note on Monday, March 10th. They set an "overweight" rating and a $29.00 price objective on the stock. Finally, Royal Bank of Canada initiated coverage on shares of Aardvark Therapeutics in a report on Monday, March 10th. They set an "outperform" rating and a $21.00 price target for the company.

Aardvark Therapeutics Trading Down 6.5 %

NASDAQ AARD traded down $0.50 on Thursday, reaching $7.24. 173,806 shares of the company's stock traded hands, compared to its average volume of 136,046. Aardvark Therapeutics has a 12 month low of $6.79 and a 12 month high of $19.58.

Remove Ads

Insider Activity

In other news, CFO Nelson Sun bought 10,000 shares of the firm's stock in a transaction dated Friday, February 14th. The stock was purchased at an average price of $16.00 per share, with a total value of $160,000.00. Following the transaction, the chief financial officer now owns 99,484 shares of the company's stock, valued at approximately $1,591,744. The trade was a 11.18 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Tien-Li Lee purchased 16,542 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $264,672.00. Following the completion of the transaction, the chief executive officer now directly owns 1,496,175 shares of the company's stock, valued at $23,938,800. This represents a 1.12 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.